Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RIPK1 | Q13546 | 9/20 | 0.55 |
| ▸ | KMO | O15229 | 1/20 | 0.35 |
| ▸ | NNMT | P40261 | 1/20 | 0.34 |
| ▸ | LOXL2 | Q9Y4K0 | 1/20 | 0.34 |
| ▸ | LRRK2 | Q5S007 | 2/20 | 0.33 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.33 |
| ▸ | MTOR | P42345 | 1/20 | 0.33 |
| ▸ | CHRM4 | P08173 | 3/20 | 0.32 |
| ▸ | WNT1 | P04628 | 1/20 | 0.32 |
| ▸ | GSK3B | P49841 | 1/20 | 0.32 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25817123 | 0.89 | RIPK1 (0.58) | RIPK1KMOLOXL2CHRM4 | |
| SCHEMBL30338930 | 0.89 | RIPK1 (0.58) | RIPK1KMOLOXL2CHRM4 | |
| SCHEMBL25816870 | 0.87 | RIPK1 (0.64) | RIPK1KMOLOXL2PIK3CAMTOR | |
| SCHEMBL30339228 | 0.87 | RIPK1 (0.64) | RIPK1KMOLOXL2PIK3CAMTOR | |
| SCHEMBL29048233 | 0.87 | RIPK1 (0.64) | RIPK1KMOLOXL2PIK3CAMTOR | |
| SCHEMBL25819773 | 0.84 | RIPK1 (0.41) | RIPK1NNMT | |
| SCHEMBL30456093 | 0.82 | RIPK1 (0.80) | RIPK1KMOCHRM4 | |
| SCHEMBL22608900 | 0.82 | RIPK1 (0.80) | RIPK1KMOCHRM4 | |
| SCHEMBL22608920 | 0.82 | RIPK1 (0.80) | RIPK1KMOCHRM4 | |
| SCHEMBL22608921 | 0.82 | RIPK1 (0.80) | RIPK1KMOCHRM4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230219937-A1 | ISOXAZOLIDINES AS RIPK1 INHIBITORS AND USE THEREOF | SANOFI (FR) | 2023-07-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230219937-A1 | ISOXAZOLIDINES AS RIPK1 INHIBITORS AND USE THEREOF | RIPK1, RIPK4, RIPK2 | RIPK1 1/4885KMO 1669/4885NNMT 3440/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.